Body fluid biomarkers and psychosis risk in The Accelerating Medicines Partnership® Schizophrenia Program: design considerations
Schizophrenia (Heidelb). 2025 May 21;11(1):78. doi: 10.1038/s41537-025-00610-4. ABSTRACT Advances in proteomic assay methodologies and genomics have significantly improved our understanding of the blood proteome. Schizophrenia …